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Background: Angiogenesis is an important step in the metastatic cascade of tumors.
Results:MMP-13 itself as well as VEGF-A secretion from fibroblasts promotes angiogenesis. Indeed,MMP-13 is well correlated
with blood vessel density in human cancer tissues.
Conclusion:MMP-13 can be a marker for prediction of malignant behaviors and a therapeutic target in cancer.
Significance: This work provides new insights regarding the role of MMP-13 in tumor angiogenesis.
Matrix metalloproteinases (MMPs) are extracellular zinc-de-
pendent endopeptidases involved in the degradation and
remodeling of extracellular matrix in physiological and patho-
logical processes. MMPs also have a role in cell proliferation,
migration, differentiation, angiogenesis, and apoptosis. We
previously identified cancer invasion-related factors by com-
paring the gene expression profiles between parent and the
highly invasive clone of cancer cells. Matrix metalloprotei-
nase-13 (MMP-13) was identified as a common up-regulated
gene by cancer invasion-related factors. Although MMP-13
slightly promoted tumor invasion, we found that MMP-13 was
involved in tumor angiogenesis. Conditioned medium from
MMP-13-overexpressing cells promoted capillary formation of
immortalized human umbilical vein endothelial cells. Further-
more, treatment with recombinant MMP-13 protein enhanced
capillary tube formation both in vitro and in vivo. MMP-13-
promoted capillary tube formation was mediated by activation
of focal adhesion kinase and ERK. Interestingly, MMP-13 pro-
moted the secretionofVEGF-A from fibroblasts and endothelial
cells. By immunohistochemical analysis, we found a possible
correlation between MMP-13 expression and the number of
blood vessels in human cancer cases. In summary, these findings
suggest that MMP-13 may directly and indirectly promote
tumor angiogenesis.
The process of metastasis consists of sequential and selective
steps, including proliferation, induction of angiogenesis,
detachment, motility, invasion into circulation, aggregation
and survival in the circulation, cell arrest in distant capillary
beds and extravasation into organ parenchyma (1, 2). Induction
of angiogenesis is considered one of the important steps in the
metastatic cascade of tumors. It is widely accepted that tumor
growth andmetastasis are angiogenesis-dependent, and hence,
blocking angiogenesis could be a strategy to arrest tumor
growth (3). The “angiogenic switch” is “off” when the effect of
proangiogenic molecules is balanced by that of anti-angiogenic
molecules, and is “on” when the net balance is tipped in favor of
angiogenesis (4, 5). Pro- and anti-angiogenic molecules can be
emanated from cancer cells, endothelial cells, stromal cells,
blood, and the extracellular matrix (ECM)3 (6). Their relative
contribution is likely to change with tumor type and site. It is
also likely to changewith tumor growth, regression and relapse.
However, the interplay between environmental and genetic
mechanisms influencing tumor angiogenesis and growth is a
complex and largely unresolved matter.
The ECM undergoes significant remodeling during tumor
progression and this is mediated largely by the extracellular
proteinases, particularly the matrix metalloproteinases
(MMPs), and themajor source of these is from the stromal cells
(7). MMPs represent a family of zinc-dependent proteinases,
which are able to degrade ECM components such as collagens
and proteoglycans and have a role in normal development and
tissue damage in various pathophysiological conditions involv-
ing arthritis, wound healing, and tumor development (8).
MMPs can be classified into subgroups, including collagenases,
stromelysins, gelatinases, and membrane-type MMPs (9).
MMPs have been implicated in the promotion of tumor inva-
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sion and metastasis for decades (10). It is now evident that
MMP function is more complex than initially thought, given
that these enzymes do more than degrade physical barriers.
MMPs also affect multiple signaling pathways that modulate
the biology of the cell in normal physiological processes and in
disease. It is now evident that someMMPs such as MMP-1, -2,
-3, -7, -9, -14, and -16 can contribute to distinct vascular events
in tumors (11). Among them, MMP-9, conveyed by inflamma-
tory cells, has a distinct role in tumor angiogenesis, mainly reg-
ulating the bioavailability of VEGF. MMP-9 enables an angio-
genic switch by making sequestered VEGF bioavailable for its
receptor VEGFR-2 in pancreatic islet tumors (12). In addition,
the direct cleavage ofmatrix-boundVEGF byMMP-3, -7, -9, or
-16 results in modified VEGF molecules with altered bioavail-
ability, which changes the vascular patterning of tumors in vivo
(13). However, the degradation of ECM components and other
extracellular molecules may generate fragments with new bio-
activities that inhibit angiogenesis (14). Thus, MMPs have dual
functions as inhibiting and promoting angiogenesis, and the
effects of MMPs on angiogenesis might be diverse.
It has recently been shown that a repair of bone fracture in
MMP-13-deficient mice is delayed, which suggests a critical
role of MMP-13 in the process of angiogenesis during the heal-
ing of fracture (15). Additionally, chicken MMP-13 was shown
to directly contribute to neovascularization, which clearly
extends the physiologic role of MMP-13 associated with carti-
lage and bone resorption to collagen remodeling in the angio-
genic process (16). MMP-13 is known as collagenase-3 and is
active against a wide variety of ECM components (17). More-
over, high expression of MMP-13 has been related to tumor
behavior and prognosis (18). Recently, it has been shown that
MMP-13 produced from stromal fibroblasts promotes angio-
genesis through increased protein level of VEGF and VEGFR-2
in cancer invasive area (19). Here, we found that MMP-13 pro-
duced by cancer cells directly and indirectly promoted tumor
angiogenesis.
EXPERIMENTAL PROCEDURES
Reagents—Active form of recombinant human MMP-13,
which truncated from theC terminuswas obtained fromChon-
drex, Inc. (Redmond, WA). This recombinant protein was
made using the pET vector system in Escherichia coli. Recom-
binant TGF- and ERK inhibitor, U0126 was obtained from
R&DSystems (Minneapolis,MN). Focal adhesion kinase (FAK)
inhibitor, FAK inhibitor 14, was obtained from Santa Cruz Bio-
technology (SantaCruz, CA).MMP-13 inhibitor, CL82198, was
obtained fromMerck Millipore (Darmstadt, Germany).
Cell Lines and Culture Conditions—Head and neck squa-
mous cell carcinoma (HNSCC) cell lines (HCS2, HSC3, HSC4,
Ca-9-22, Ho-1-N-1, and Ho-1-U-1) were provided by the Japa-
nese Collection of Research Bioresources Cell Bank. These cells
were maintained in RPMI 1640 (Nacalai tesque, Inc., Kyoto,
Japan) supplemented with 10% heat-inactivated FBS (Invitro-
gen) and 100 units/ml penicillin-streptomycin (Invitrogen)
under the condition of 5% CO2 in air at 37 °C. Immortalized
human umbilical vein endothelial cells (HUVECs; HuhT1 cells)
were used in this study. HuhT1 cells were previously estab-
lished by transfection with human telomerase reverse tran-
scriptase (20). HuhT1 cells was maintained in HuMedia-EG2
(Kurabo,Okayama, Japan) under the condition of 5%CO2 in air
at 37 °C.Normal fibroblasts were obtained from gingival tissues
using standard explant techniques (21). The tissues were
obtained undergoing routine dental surgery in the Department
ofOral Surgery (HiroshimaUniversityHospital). Normal fibro-
blasts weremaintained in DMEM supplemented with 10% FBS.
Only cells between passages three and five were used in this
study.
RT-PCR—Using RNeasy mini kit (Qiagen, Hilden, Ger-
many), total RNA from cultures of confluent cells was isolated.
These isolateswere quantified and their puritywas evaluated by
spectrophotometer. The cDNA was synthesized from 1 g of
total RNA according to ReverTra Dash (Toyobo Biochemicals,
Tokyo, Japan). We used the following primers: human MMP-
13, 5-ttgagctggactcattgtcg-3 (forward) and 5-ggagcctctcagt-
catggag-3 (reverse); human glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), 5-tccaccaccctgttgctgta-3 (for-
ward) and 5-accacagtccatgccatcac-3 (reverse). Aliquots of
total cDNA were amplified with 1.25 units of rTaq-DNA
polymerase (Qiagen), and this amplificationwas done in a ther-
mal cycler (MyCyler, Bio-Rad, Richmond, CA) for 30 cycles
after initial 30 s of denaturation at 94 °C, annealing for 30 s at
60 °C, and extension for 1 min at 72 °C in all primers used. The
amplification reaction products were resolved on 1.2% agarose/
TAEgels (Nacalai tesque), electrophoresed at 100mV, and then
finally visualized by using ethidium bromide.
Generation of MMP-13-overexpressing Cells—pcDNA3.1-
FLAG-MMP-13 expression vector was kindly provided by Dr.
Michael Byrne (Harvard Medical School). We transfected
MMP-13 into HSC3 cells. Then, G418 (300 g/ml; Invivogen,
San Diego, CA) was added to the culture medium after 48 h of
transfection. After 2 weeks of G418 selection, we obtained the
stable pool clones. Cell transfections were performed using
FuGENE 6HD (Roche Applied Science) according to the man-
ufacturer’s instruction. Conditionedmedia were collected after
incubation with RPMI without FBS for 2 days.
Silencing by siRNA—Logarithmically growing HSC4 and
Ho-1-N-1 cells were seeded at a density of 105 cells/dish (6 cm)
and transfected with 20 nM siRNA by using Oligofectamine®
RNAi MAX (Invitrogen), according to the manufacturer’s
instructions. Forty-eight hours after transfection, the cells were
prepared and analyzed by Western blot analysis. At the same
time, we changed to new medium, incubated for 48 h, and col-
lected the conditioned medium. The following siRNA oligonu-
cleotides were obtained from B-Bridge International, Inc.
(Mountain View, CA): MMP-13, gaugaaaccuggacaaguaTT. A
scrambled sequence without significant homology to rat,
mouse, or human gene sequences was used as a control.
Western Blot Analysis—Western blotting was carried out as
described previously (22). The protein concentrations were
measured by Bradford protein assay (Bio-Rad). Twenty g of
protein was subjected to 10% polyacrylamide gel electrophore-
sis, followed by electroblotting onto a nitrocellulose filter. For
detection of the immunocomplex, the ECL Western blotting
detection system (Amersham Biosciences) was used. Anti-
MMP-13 monoclonal antibody (Fuji Company Industries,
Tokyo, Japan), anti-FLAG monoclonal antibody (Sigma), and
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anti--actin monoclonal antibody (Sigma), -smooth muscle
actin (-SMA), anti-phospho-FAK (Tyr-576/Tyr-577) mono-
clonal antibody (Cell Signaling Technology, Beverly,MA), anti-
phospho-Src (Tyr-416) polyclonal antibody (Cell Signaling
Technology), anti-phospho-ERK (Thr-202/Tyr-204) monoclo-
nal antibody (Santa Cruz Biotechnology, Santa Cruz, CA), anti-
FAK polyclonal antibody (Cell Signaling Technology), anti-Src
polyclonal antibody (Cell Signaling Technology), and anti-ERK
monoclonal antibody (Cell Signaling Technology) were used.
For detection of phosphorylated proteins, membranes were
blockedwith 3%milk/TBS-T and incubatedwith phospho-spe-
cific antibodies overnight at 4 °C. After washing in TBS-T,
membranes were incubated with specific secondary antibodies,
and the proteins were visualized as described previously.
MMP-13 Activity—TheMMP-13 activity was determined by
a MMP-13 inhibitor assay kit (Chondrex, Inc., Redmond, WA,
distributed by IWAI Chemicals Company, Japan, catalog no.
3003). A designate reaction was performed in the 96-well
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microtiter plate according to the manufacturer’s instructions.
The assay procedure was separated into two stages. First,
diluted recombinant humanMMP-13 (10g/ml) with dilution
buffer B or conditioned medium (from control cells, MMP-13-
overexpressing cells or MMP-13 siRNA-treated cells) was acti-
vated by adding 5 l of aminophenylmercuric acetate at 35 °C
for 60min. Second, appropriate amounts of test sampleswith or
without several inhibitors (U0126, FAK inhibitor 14 and
CL82198) that diluted by solution B and reaction buffer to the
wells were added to adjust the final volume to 160l. The reac-
tion was initiated by adding 100l of substrate solution to each
well. The collagenase reaction was stopped by adding 10 l of
the stop solution to each well after incubating at room temper-
ature for 30 min. The reaction fluorescence intensity was
determined at emission 450 nm and excitation 345 nmwith
Varioskan Flash (Thermo Scientific). TheMMP-13 activity was
determined by comparingwith a standard response curve using
buffer instead of inhibitor in similar conditions. All assays were
carried out in three replications.
Migration Assay—Migration activity was measured by the
use of a 24-well cell culture insert with 8-m pores (Falcon
Becton Dickinson). The lower compartment contained 0.5 ml
of conditionedmedium or serum-free mediumwith or without
100 ng/ml of recombinant MMP-13. After trypsinization, 5 
104 cells were resuspended in 100l of serum-freemedium and
placed in the upper compartment of the cell culture insert for
4 h. To examine the activity of migration, the cells that had
penetrated onto the lower side of the filter were fixed with for-
malin and stained with hematoxylin. These were assayed three
times.
In Vitro Angiogenesis by HUVECs—An angiogenesis assay kit
obtained fromKurabo (Osaka, Japan)was used according to the
manufacturer’s instructions with minor modifications (23).
HUVECs were treated with conditioned medium from MMP-
13-overexpressing cells or control cells (1:1 mixture with the
medium). HUVECs were also treated with different concentra-
tions of recombinant MMP-13 protein (0, 50, 100 and 200
ng/ml). VEGF-A (2 g/ml) was used as a positive control, and
suramin (1 mM) was used as a negative control. We examined
three wells/data point in a single experiment. The media were
changed every 3 days. After 12 days, the cells were fixed at room
temperature with cold 70% ethanol for 30 min. The cells were
incubated with the anti-human CD31 antibody for 1 h at 37 °C
and further with an alkaline phosphatase-conjugated goat anti-
mouse IgG antibody. Visualizationwas achievedwith 5-bromo-
4-chloro-3-indolyl phosphate-nitrobluetetrazolium. Capillary
tube score was estimated with the Chalkley count method
under a bright-field microscope (24).
RatAortic RingAngiogenesis Assay—The effect of samples on
angiogenesis was studied by culturing aortic explants in three-
dimensional matrix gels according to the protocol described by
Bauer et al. (25). Thoracic aorta was excised from 7-week-old
male Sprague-Dawley rat, and the fibroadipose tissue was
removed. The aorta was sectioned into 1-mm-long cross-sec-
tions, rinsed with EBM-2 medium (Lonza, Walkersville, MD),
placed on theMatrigel-coatedwells, coveredwith additional 50
l of Matrigel, and allowed to form a gel for more than 30 min
at 37 °C, 5% CO2. Afterward, control was treated with EBM-2
medium only, and the test sample was treated with EBM-
2 medium containing recombinant MMP-13 protein. Each
medium was added every other day. All assays were performed
by using five aortic rings per sample. Aortic rings were photo-
graphed on day 15. The area of angiogenic sprouting was cal-
culated using Image-Pro Plus software program (Media Cyber-
netics). Microvessel densities were reported in square pixels.
VEGF-A Quantification—A fixed number of fibroblasts cul-
tured inmediumwithout FBSwere treatedwithMMP-13 (0, 10
and 50 ng/ml) and/or TGF- (1 ng/ml) for 24 h. The concen-
tration of VEGF-A in the culture medium was quantified with
commercial ELISA kit according to themanufacturers’ instruc-
tions (Pierce Biotechnology, Rockford, IL).
Tissue Samples—Sixty-seven tissue samples of human
HNSCCwere retrieved from the Surgical Pathology Registry of
University of Peradeniya and Oral and Maxillofacial unit,
KandyHospital, after being approved by the Ethical Committee
of each institution. Informed consent obtained fromall patients
was verbal for this study, and then signature was obtained from
all patients. Sixty-seven Sri Lankan HNSCC cases (42 male,
nine female and 16 unknown; average agewas 50.2 13.2) were
surgically resected from 1998 to 2004 before radiochemo-
therapy. Clinical information including metastasis was gath-
ered from surgical records of the patients. Tissues were fixed in
10% buffered formalin and embedded in paraffin.
Immunohistochemistry—Tumor tissues were fixed in 10%
formalin, embedded in paraffin, and cut into 4-m thick sec-
tions. For immunohistochemical staining, tissue sections were
deparaffinized in xylene and rehydrated in descending grades of
ethanol. Endogenous peroxidase activity was blocked with
FIGURE 1. Identification of MMP-13. A, schema shows the strategy to identify MMP-13. Periostin, IFITM1, and Wnt-5b are identified as the invasion-related
molecules by comparing the gene expression profile between the parent (MSCC-1 cells) and a highly invasive clone (MSCC-Inv1 cells). To identify common
up-regulatedgenes,we compared thegeneexpressionprofiles of control versusperiostin-overexpressing cells, control versus IFITM1-overexpressing cells, and
control versusWnt-5b-overexpressing cells. MMP-13 is commonly up-regulated among periostin-, IFITM1-, andWnt-5b-overexpressing cells. B, expression of
MMP-13 inHNSCC cell lines. Expression ofMMP-13mRNA in six HNSCC cell lines: HSC2, HSC3, HSC4, Ca-9-22, Ho-1-N-1, andHo-1-U-1was examinedby RT-PCR.
GAPDHwas used as a loading control. C, generation ofMMP-13-overexpressing cells. pcDNA3.1-FLAG-MMP13was transfected into HSC3 cells. After selection,
we obtained four stable clones and one stable pool clone of MMP-13-overexpressing cells. Ectopic expression of MMP-13 was examined by immunoblotting
with an anti-FLAG antibody. In further experiments, clone 1 was used. D, MMP-13 ability was determined by a MMP-13 inhibitor assay kit as described under
“Experimental Procedures.” Conditioned medium was collected from control HSC3, MMP-13-overexpressing HSC3, control Ho-1-N-1, MMP-13 siRNA-treated
Ho-1-N-1, control HSC4, andMMP-13 siRNA-treatedHSC4 cells. The reactionwas initiatedby adding 100l of substrate solution, and the reaction fluorescence
intensity was determined at emission  450 nm and excitation  345 nm. The graph shows fluorescence intensity. All assays were carried out in three
replications. E, ectopic expression of FLAG-MMP-13 was examined by immunoblotting with an anti-FLAG antibody. -Actin expression was used as a loading
control. Expression ofMMP-13 in condensed conditionedmediumwas detected by immunoblottingwith an anti-MMP-13 antibody. F, MMP-13 knockdown in
HSC4 andHo-1-N-1 cells. MMP-13 siRNAwas transfected into HSC4 andHo-1-N-1 cells. A scrambled sequence that does not show significant homology to rat,
mouse, or human gene sequenceswas used as a control. After 48 h, cells were collected, andMMP-13 expressionwas examined byWestern blot (WB) analysis.
-Actin expression was used as a loading control.
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FIGURE 2. Involvement of MMP-13 in migration and capillary tube formation of HUVECs. A, migration activity by conditioned medium from MMP-13-
overexpressing cells. Migration activity wasmeasured by the use of a 24-well cell culture insert with 8-mpores. The lower compartment contained 0.5 ml of
conditionedmedium fromempty vector-transfectedHSC3 cells (control CM) orMMP-13-overexpressingHSC3 cells (MMP-13 CM). After trypsinization, 5 104
of immortalized HUVECs (HuhT1) were resuspended in 100l of serum-freemedium and placed in the upper compartment of the cell culture insert for 4 h. To
examine the activity of migration, the cells that had penetrated onto the lower side of the filter were fixed with formalin and stained with hematoxylin. The
upper panel shows the representative area of penetrated cells. The lower graph shows the average number of penetrated cells. The bars show the average
values and S.D. of three independent experiments. *, significantly different from control at p 0.05. B, upper panel shows the representative area of capillary
tube formation by conditionedmedium fromempty vector-transfectedHSC3 cells (control CM) orMMP-13-overexpressingHSC3 cells (MMP-13 CM) (40). An
angiogenesis assay kit was used according to the manufacturer’s instructions with minor modifications. HUVECs were treated with mixture of conditioned
mediumandHuMedia-EG2 in apercentageof 1:1. Themixedmediawere changedevery 3days. After 12days, the cellswere fixed and stainedwith anti-human
CD31 antibody as described under “Materials and Methods.” The lower graph shows the average capillary tube score after conditioned medium treatment.
Capillary tube scorewas estimatedwith the Chalkley countmethod under a bright-fieldmicroscope. The values representmeans of capillary tube score S.D.
based on three wells/data point in a single experiment. *, significantly different from control at p 0.05. C, migration activity of HuhT1 cells by conditioned
medium from control or MMP-13 siRNA-treated cells. MMP-13 siRNA were transfected into HSC4 and Ho-1-N-1 cells. Migration activity was measured as
described in A. The upper panel shows the representative area of penetrated cells. The lower graph shows the average number of penetrated cells. The bars
show the average values and S.D. of three independent experiments. *, significantly different fromcontrol atp 0.05.D, upper panel shows the representative
area of capillary tube formation by conditionedmedium from control orMMP-13-depleted cells (40). Capillary tube formationwas examined as described in
B. The lower graph shows the average capillary tube score after conditioned medium treatment. Capillary tube score was estimated with the Chalkley count
method under a bright-field microscope. The values represent means of capillary tube score S.D. based on three wells/data point in a single experiment. *,
significantly different from control at p 0.05.
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methanol containing 0.3% H2O2 for 30 min. Antigen retrieval
was done by the microwaving using a citrate phosphate buffer
(pH6.0), and then the sectionswere incubatedwith the primary
antibody at 4 °C overnight. Immunohistochemical staining was
carried out by amonoclonal anti-MMP-13 antibody (Fuji Com-
pany Industries, 1:80). For detection of the reaction after incu-
bation with secondary antibodies, we used diaminobenzidine
(DAKO, Glostrup, Denmark). The sections were counter-
stained by hematoxylin and dehydrated in ascending grades of
ethanol, and finally, the slides were mounted. By considering
the percentage of positive cells and the overall staining inten-
sity, MMP-13 was considered positive if over 10% of the tumor
cells showed strong or diffuse staining. If less than 10% of the
cells showed weak or no staining, it was considered negative.
Assay for Blood Vessel Density—CD34 is an antigen present
in hematopoietic progenitor cells and endothelial cells. Anti-
CD34 antibody is a highly sensitive marker for endothelial cell
differentiation and has also been studied as a marker for vascu-
lar tumors. To investigate the relation between angiogenesis
andMMP-13, we stained all HNSCC caseswithCD34 endothe-
lial marker (Novocastra Laboratories Ltd., Newcastle, UK) by
SABC method. To assess blood vessel density, we performed
histomorphometric analysis. Three representative photomi-
crographs (areas where MMP-13 positivity were detected
including invasive front) were taken from each case stained
with CD34. First, we went through all the sections stained with
MMP-13 and CD34 antibodies. The area was selected by the
following criteria: (i) the expression of MMP-13, (ii) the
included invasive tumor front, and (iii) the high number of
blood vessels. Photographs of those tumors were taken in close
proximity to MMP-13-expressing area including the invasive
front. For MMP-13-negative cases, three areas from the inva-
sive front were selected. Any positively stained endothelial cell
or endothelial cell cluster, with or without a lumen, was consid-
ered as a single, countable blood vessel. Stromal area was
quantitatively analyzed using digital image (Adobe Photo-
shop and Scion Image software). From each figure, total
counts of blood vessels per stromal area were taken, and the
average was calculated. The results were then compared with
MMP-13 expression.
Statistical Analysis—A p value  0.05 was required for
assessing the significance. Correlation between variables was
estimated using Fisher’s exact test, and for correlation between
MMP-13 expression and blood vessel density, a Welch test was
used.
RESULTS
MMP-13 Promotes Angiogenesis—We previously identified
periostin, interferon-induced transmembrane protein 1
(IFITM1), and Wnt-5b as cancer invasion-related factors by
comparing the gene expression profiles between parent and
highly invasive clone of a cancer cell line (22). MMP-13 was
identified as a common up-regulated molecule by comparing
the gene expression profiles between control cells and perios-
tin-overexpressing cells, control cells and IFITM1-overex-
pressing cells, and control cells and Wnt-5b-overexpressing
cells (Fig. 1A) (26). It is known thatMMP-13 is highly expressed
in various tumors and is related to tumor behavior and progno-
sis (18). To know the role of MMP-13 in cancer development,
we generatedMMP-13-overexpressing cancer cells. Expression
of MMP-13 mRNA was examined in six head and neck cancer
cell lines (Fig. 1B). Among six cell lines, HSC2 and HSC3 cells
showed lower expression of MMP-13 mRNA. Expression level
of MMP-13 in these cells was lower than that in other cancer
cells. Therefore, we transfected a FLAG-MMP-13 plasmid into
HSC3 cells. Then, we obtained four stable clones and one stable
pool clone ofMMP-13-overexpressing cells (Fig. 1C). All stable
clones highly expressed ectopic MMP-13 (Fig. 1C). In further
experiments, clone 1was used. By usingMMP-13-overexpress-
ing cells, we examined the role of MMP-13 in cell growth and
invasion. MMP-13 overexpression did not affect cell prolifera-
tion and slightly promoted the invasion of HNSCC cells (data
not shown).We also confirmed that conditionedmedium from
MMP-13-overexpressing cells had a higher protease activity
than that from control cells (Fig. 1D).
MMP-13 has recently been shown to play a critical role in the
process of angiogenesis during the healing of fracture (15).
Here, we examined the role of MMP-13 in angiogenesis.
MMP-13 secretion was detected in conditioned medium from
MMP-13-overexpressing-HSC3 cells by Western blot analysis
(Fig. 1E). Expression level of ectopic MMP-13 in MMP-13-
overexpressing HSC3 cells was similar to that of endogenous
MMP-13 in Ho-1-N-1 or HSC4 cells (Fig. 1F). By using condi-
tioned medium fromMMP-13-overexpressing cells, we exam-
ined the migration of immortalized HUVECs. The HuhT1 cell
line was previously established from HUVECs by transfection
with human telomerase reverse transcriptase (20). Conditioned
medium fromMMP-13-overexpressing cells promoted migra-
tion of HuhT1 cells (Fig. 2A). Interestingly, conditioned
medium from MMP-13-overexpressing cells significantly pro-
moted capillary tube formation, in comparison with that from
FIGURE 3.MMP-13 promoted angiogenesis both in vitro and in vivo. A, effect of MMP-13 on the proliferation of HuhT1 cells. Cells were plated on 24-well
plates, and trypsinized cells were counted by Cell Counter at 0, 2, 4, and 6 days after adding recombinant MMP-13 protein (100 or 200 ng/ml). B, migration
activity by recombinantMMP-13 protein.Migration activitywasmeasured as described in Fig. 1E. The upper panel shows the representative area of penetrated
cells. The lower graph shows the average number of penetrated cells. The bars show the average values and S.D. of three independent experiments. C, upper
panel shows the representative area of capillary tube formation by treatment with recombinant MMP-13 protein (50, 100, and 200 ng/ml) (40). VEGF-A (2
g/ml) was used as a positive control, and suramin (1 mM) was used as a negative control. Capillary tube formation was examined as described in Fig. 1F. The
lower graph shows the average capillary tube score after treatment with recombinant MMP-13 protein. The capillary tube score was estimated with the
Chalkley countmethod under a bright-fieldmicroscope. The values represent means of capillary tube score S.D. based on three wells/data point in a single
experiment. *, p 0.05. D, upper panel shows representative case of culturing aortic explants in three-dimensional matrix gels with or without recombinant
MMP-13 protein (100 ng/ml). Excited thoracic aorta (1-mm-long cross-sections) was placed on theMatrigel-coatedwells and coveredwith an additional 50l
of Matrigel. Afterward, Control was treated with EBM-2 medium only or EBM-2 medium containing recombinant MMP-13 protein. Each medium was added
every other day. All assays were performed by using five aortic rings per sample. Aortic rings were photographed on day 15. The area of angiogenic sprouting
was calculated using Image-Pro Plus software program (Media Cybernetics). The lower graph shows microvessel densities in square pixels.
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empty vector-transfected HSC3 cells (Fig. 2B). Moreover, we
examined MMP-13 knockdown in Ho-1-N-1 or HSC4 cells
with MMP-13 expression. MMP-13 siRNA reduced MMP-13
expression and protease activity (Fig. 1, D and F). Conditioned
medium from MMP-13-depleted cells suppressed migration
and capillary tube formation (Fig. 2, C and D).
To exclude other factors in conditioned medium, we used
recombinant MMP-13 protein for in vitro angiogenesis assay.
We examined the effect of recombinant MMP-13 protein on
cell growth and migration of HuhT1 cells. Treatment with
recombinant MMP-13 protein did not significantly promote
cell growth and migration of HuhT1 cells (Fig. 3, A and B). For
FIGURE 4.MMP-13-promoted angiogenesis is mediated by FAK and ERK signaling pathway. A, levels of total and phosphorylated forms of FAK, Src, and
ERK after treatment of HuhT1 cells with MMP-13 (100 ng/ml) shown by Western blotting. -Actin expression was used as a loading control. HuhT1 cells were
seeded on a culture dish. After incubation for 24 h, medium was changed to HuMedia without FBS and growth factors. After 4 h, the recombinant MMP13
protein (100 ng/ml) was added and the cells were incubated for indicated times. B, phosphorylated forms of FAK (Tyr-576/577), Src (Tyr-416) and ERK
(Thr-202/Tyr-204) in thepresence ofMMP-13 (100ng/ml) after treatmentwith 10MFAK inhibitor (FAK inhibitor 14) or 10MERK inhibitor (U0126). Expression
of total FAK or ERKwas used as a loading control. C, upper panel shows the representative area of capillary tube formation by FAK inhibitor (FAK inhibitor, 14 or
10M) or ERK inhibitor (U0126, 10M)withorwithoutMMP-13 (100ng/ml) (40). The lower left graph shows the average tubule score after 10MFAK inhibitor
(FAK inhibitor 14) or 10Mof ERK inhibitor (U0126)with orwithout 100ng/ml of recombinantMMP-13protein. The lower right graph shows the average tubule
score after FAK inhibitor (0.1 and 1M) or ERK inhibitor (0.1 and 1M)with or without 100 ng/ml of recombinantMMP-13 protein. The values representmeans
of capillary tube score  S.D. based on three wells/data point in a single experiment. D, to examine the effect of protease inhibition on FAK and ERK
phosphorylation, CL-821198,which is a selective inhibitor ofMMP-13 through thebinding to theS1pocket ofMMP-13with itsmorpholine ringadjacent to the
catalytic zinc atom, was used. HuhT1 cells were seeded on a culture dish. After incubation for 24 h,mediumwas changed to HuMediawithout FBS and growth
factors. After 4 h, CL-821198 (10g/ml) and/or recombinant MMP13 protein (100 ng/ml) were added, and the cells were incubated for 1 h. Levels of total and
phosphorylated formsof FAKandERKwasexaminedbyWesternblotting. E, capillary tube formationwasexaminedbyusinganangiogenesis assay kit. HUVECs
were treatedwith the recombinantMMP-13proteinwith orwithout CL-821198 (5 and10g/ml), and themediumwas changedevery 3days. After 12days, the
cells were fixed and stained with anti-human CD31 antibody. The graph shows the average capillary tube score after treatment with recombinant MMP-13
protein. The capillary tube scorewas estimatedwith the Chalkley countmethod under a bright-fieldmicroscope. The values representmeans of capillary tube
score S.D. based on three wells/data point in a single experiment. *, p 0.05.
FIGURE 5. VEGF-A secretion by MMP-13 treatment in fibroblasts. A, fibroblasts were seeded on a culture dish. After incubation for 24 h, medium was
changed to DMEM without FBS. After 24 h, MMP-13 (0, 10, and 50 ng/ml) and TGF- (1 ng/ml) with or without MMP-13 (50 ng/ml) were treated for 24 h. The
concentrationof VEGF-A in the culturemediumwasquantifiedwith commercial ELISA kits according to themanufacturer’s instructions.B, after treatmentwith
MMP-13 (0, 10, and 50 ng/ml) or TGF- (1 ng/ml) with or without MMP-13 (50 ng/ml) for 24 h, fibroblasts were collected. Expressions of VEGF-A, -SMA, and
-actin were examined by immunoblotting. The densitometric analysis of VEGF-A expression was performed. VGEF-A/-actin ratio is shown. C, HuhT1 cells
were seededon a culture dish. After incubation for 24 h,mediumwas changed toHuMediawithout FBS andgrowth factors. After 4 h, the recombinantMMP13
protein (100ng/ml)with orwithout 10Mof FAK inhibitor (FAK inhibitor 14), 10Mof ERK inhibitor (U0126) or 10g/ml of CL-821198were added and the cells
were incubated for 1 h. Expression of VEGF-A and -actin were examined by immunoblotting. The concentration of VEGF-A in the culture medium was
quantified with commercial ELISA kits according to the manufacturer’s instructions. D, fibroblasts were seeded on a culture dish. After incubation for 24 h,
mediumwas changed toDMEMwithout FBS. After 24 h,MMP-13 (0, 50, and 100 ng/ml) and TGF- (1 ng/ml) with orwithoutMMP-13 (100 ng/ml) were treated
for 24 h.Moreover, we treatedCL-821198 (10g/ml). The concentration of VEGF-A in the culturemediumwas quantifiedwith commercial ELISA kits according
to the manufacturer’s instructions.
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in vitro angiogenesis assay, we used VEGF-A as a positive con-
trol and suramin as a negative control. Similarly to conditioned
medium from MMP-13-overexpressing cells, treatment with
MMP-13 protein significantly promoted capillary tube forma-
tion in a concentration-dependent manner (Fig. 3C). Surpris-
ingly, capillary tube score of MMP-13 treatment was similar to
that of VEGF-A (Fig. 3C). However, MMP-13 did not signifi-
cantly stimulate microvessel outgrowth from aorta comparing
with control (Fig. 3D).
To clarify the mechanism ofMMP-13-promoted angiogene-
sis, we examined the involvement of several intracellular signal-
ing molecules such as FAK, Src, and ERK by Western blotting
using phosphorylation specific antibodies in HuhT1 cells after
adding recombinantMMP-13 protein. Increased phosphoryla-
tion of FAK and ERK was observed after adding MMP-13 pro-
tein (Fig. 4A). Todemonstrate the involvement of FAKandERK
in MMP-13-promoted angiogenesis, we examined capillary
tube formation after treatment with FAK inhibitor (FAK inhib-
itor 14) or ERK inhibitor (U0126) together with recombinant
MMP-13 protein. We confirmed that treatment with FAK
inhibitor 14 or U0126 suppressed FAK or ERK activity, respec-
tively (Fig. 4B). Both inhibitors inhibited MMP-13-promoted
capillary tube formation in a concentration-dependentmanner
(Fig. 4C). Both inhibitors also inhibited capillary tube formation
without MMP-13 treatment in a concentration-dependent
manner (Fig. 4C), suggesting that the FAK and ERK signaling
pathwaymay be a conventional pathway of angiogenesis.More-
over, FAK inhibitor did not influence on ERK activity and ERK
inhibitor did not influence on FAK activity inMMP-13-treated
endothelial cells (data not shown), suggesting that the inhibi-
tory effects exerted by either FAK or ERK inhibitor are sepa-
rated. These findings suggest that MMP-13 may promote
angiogenesis via a conventional pathway.
ToknowwhetherERKorFAKactivity inducedbyMMP-13was
caused by protease activity ofMMP-13, we examined the effect of
protease inhibition on FAK and ERK phosphorylation by using
CL-821198, which is a selective inhibitor ofMMP-13 through the
binding to the S1 pocket of MMP-13 with its morpholine ring
adjacent to the catalytic zinc atom. CL-821198 treatment did not
influence on ERK or FAK activity in HuhT1 cells (Fig. 4D). This
finding indicates that ERK or FAK activity induced byMMP-13 is
not caused by protease activity ofMMP-13.Wealso examined the
effectofCL-821198oncapillary tube formation.CL-821198 inhib-
ited MMP-13-promoted tube formation. This finding suggests
thatMMP-13 activitymay affect to capillary tube formation via an
ERK- or FAK-independent manner (Fig. 4E).
MMP-13 Promotes VEGF-A Secretion in Fibroblasts and
Endothelial Cells—A recent report shows that esophageal
squamous cell carcinoma-derived TGF- regulates angiogene-
sis through the release of VEGF from fibroblasts (27). We
examined whether MMP-13 affected the release of VEGF from
fibroblasts or endothelial cells as a similar function of TGF-.
Normal fibroblasts were obtained from gingival tissues using
standard explant techniques (21). The level of VEGF-A secre-
tion by fibroblasts was measured after being induced by
MMP-13 with/without the presence of TGF-. Interestingly,
MMP-13 could promote the secretion of VEGF-A, especially in
the presence of TGF- (Fig. 5A). It is known that paracrine
tumor-derived growth factors activate the cancer-associated
fibroblasts, which undergo a myofibroblastic transdifferentiation
defined by an elongated spindle shape, and the expression of con-
tractile -SMA and vimentin (28). Therefore, we examined the
expression of-SMAafterTGF-orMMP-13 treatment in fibro-
blasts. As previously reported, TGF- induced-SMAexpression
in fibroblasts (Fig. 5B). Although MMP-13 itself did not induce
-SMA expression in fibroblasts, both TGF- and MMP-13
induced higher expression of -SMA in comparison with the
expression level of -SMA induced by TGF- (Fig. 5B).
Moreover,we examinedwhetherMMP-13-promotedVEGF-A
secretion from the endothelial cell line HuhT1 or not. Interest-
ingly, the expression and secretion levels of VEGF-A were
increased by MMP-13 treatment (Fig. 5, C and D). Induction of
VEGF-A in HuhT1 cells was partially dependent on ERK activity
but not on FAK activity and MMP-13 protease activity (Fig. 5, C
andD).
MMP-13 Is Highly Expressed in Human Cancer Tissues—To
demonstrate in vitro and in vivo evidence ofMMP-13-mediated
angiogenesis, we examined the expression of MMP-13 and
its relationship with tumor angiogenesis in clinical cancer
cases.We examined the immunohistochemical expression of
MMP-13 in 20 normal oral epithelium and 67 HNSCC tissues.
Positive expression of MMP-13 was observed in 0 of 20 (0%)
normal oral epithelium and 54 of 67 (81%)HNSCCcases (Fig. 5,
A and B, and Table 1). We compared MMP13 expression with
metastasis in HNSCC cases. MMP-13 expression was well cor-
related withmetastasis (Table 1). Then, we comparedMMP-13
expression with the number of blood vessels in HNSCC cases.
The number of blood vessels was examined by staining using anti-
CD34 antibody. CD34 is an antigen present in hematopoietic pro-
genitor cells and endothelial cells. Anti-CD34 antibody is a highly
sensitive marker for endothelial cell differentiation and has also
been studied as a marker for vascular tumors. We observed an
increased number of blood vessels at the invasive front of the
MMP-13 positive tumor cases, compared with theMMP-13 neg-
ative cases (p  0.05) (Fig. 6, A and B). The average number of
blood vessel density assessed by histo-morphometric analysis was
41.4  13.0 and 76.2  26.6 in MMP-13 negative and positive
cases, respectively (p 0.05) (Fig. 6C and Table 1).
DISCUSSION
Angiogenesis, the formation of new blood vessels from pre-
existing ones, is a crucial step in tumor growth, progression,
and metastasis. Regulation of angiogenesis in vivo is complex
and is controlled by a variety of factors. Among them, VEGF is
considered to play a dominant role. It has been well established
that VEGF promotes a cancer progression by up-regulating
TABLE 1
Correlation between MMP-13 expression and clinicopathologic find-
ings in HNSCC
MMP-13 expression
No. of cases Low High p value
Non-neoplastic epithelium 30 30 (100%) 0 (0%) p 0.001
HNSCC 67 13 (19.4%) 54 (80.6%)
Metastasis
 30 7 (23.3%) 23 (76.7%)
 37 6 (16.2%) 31 (83.8%)
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microvessel density (3). MMPs are zinc metalloenzymes with
the ability to degrade the components of the ECM. Their action
is crucial during the progression of cancer because they allow
the remodeling of the surrounding healthy tissues and enable
local invasion (8). MMP-13 is known as collagenase-3, which
has the ability to degrade fibrillar collagen (29).However, itmay
also act as a potent gelatinase by degrading a wide variety of
extracellular matrix components (30, 31). MMP-13 is overex-
pressed in a variety of tumors from such as head and neck,
laryngeal, breast, chondrosarcoma, gastric, colorectal, vulvar
carcinomas and cutaneous malignant lymphoma (17, 32–39).
Inmostmalignancies,MMP-13 has been correlatedwith tumor
invasion, metastasis, and poor prognosis in patients (34, 35, 37,
39, 41). MMP-13 is predominantly expressed by tumor cells at
the tumor invasive front and to some extent by stromal fibro-
blasts surrounding tumor cells (33, 41). Our immunohisto-
chemical finding that MMP-13 expression is frequently
observed, but no statistical correlation was observed in
MMP-13 expression andmetastasis inHNSCC (Table 1). Aswe
used biopsy cases in this study, HNSCC cases with high expres-
sion of MMP-13 may have a potential to metastasize later.
Indeed, MMP-13 expression was well correlated with number
of blood vessels. Thus, it is well accepted that MMP-13 is
involved in tumor progression.
In the present study, we demonstrate the novel role of
MMP-13 in tumor angiogenesis. Although there is a study sug-
gesting a role of MMP-13 in keratinocyte migration and angio-
genesis during the healing of fracture (43), the role of MMP-13
in tumor angiogenesis has not been fully elucidated. It is known
that someMMPs such as MMP-1, -2, -3, -7, -9, -14 and -16 are
involved in tumor angiogenesis via the regulation of bioavail-
ability of VEGF-A (11). Distinct from the function of other
MMPs in angiogenesis, MMP-13 promoted angiogenesis
through an increased number of blood vessels at the invasive
front of the tumor andup-regulation ofVEGF-A secretion from
fibroblasts and endothelial cells (Fig. 7). We also found that
MMP-13 promoted capillary tube formation was mediated by
activation of FAK and ERK. FAK is a cytoplasmic tyrosine
kinase that plays critical roles in integrin-mediated signal trans-
ductions and also participates in signaling by other cell surface
receptors (44). Extensive studies in FAK knock-out mouse
models indicated a critical role of FAK in angiogenesis during
FIGURE 6.MMP-13 expression is well correlatedwith the number of blood vessels in human cancer cases. A, immunohistochemical staining of MMP-13
and CD34 in normal oral epithelium andHNSCC. Representative cases ofMMP-13 expression in normal oral epithelium andHNSCC are shown. Representative
cases of CD34 expression in HNSCC cases with or without MMP-13 expression are also shown. B, graph shows the number of cases with or without MMP-13
expression in 67HNSCC cases. *, p 0.05.C, graph shows the average number of blood vessels inHNSCC caseswith orwithoutMMP-13 expression. *, p 0.05.
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embryonic development (45). Moreover, the increased expres-
sion of FAK in cancer cells has been suggested to play a role in
the tumor angiogenic switch to promote aggressive tumor pro-
gression andmetastasis (46). However, Baek et al. (47) found that
theMEK/ERKpathway is involved in endothelial cell proliferation
through up-regulation of positive cell cycle proteins and down-
regulation of negative cell cycle proteins. Thus, activation of FAK
and ERK is critically involved in angiogenesis. Indeed, treatment
with FAK inhibitor or ERK inhibitor strongly inhibited the capil-
lary tube formation of endothelial cells, suggesting that FAK and
ERK signaling are essential in angiogenesis. Although MMP-13
has central roles in modulating extracellular matrix degradation
through its direct matrix degrading capability as well as having a
key involvement in the activation of otherMMPs (7), FAKor ERK
activity induced byMMP-13 was notmediated bymatrix degrad-
ing capability (Fig. 4D).Our findings suggest thatMMP-13-driven
angiogenesismay bemediated by a conventional pathway via acti-
vation of FAK and ERK.However, themechanism of ERK or FAK
activation byMMP-13 is still unclear.
The tumor tissue consists of a dynamic mixture of tumor
cells, fibroblasts, endothelial cells, and immune cells that all
work together to drive tumor progression (48). Activated fibro-
blasts, also known as cancer-associated fibroblasts within the
tumor microenvironment, is preceded by the chemoattraction
and migration of precursor cells, which can either arise from
the surrounding host fibroblasts or from circulatingmesenchy-
mal precursor cells (40, 42, 49). Cancer-associated fibroblasts
are activated by paracrine tumor-derived growth factors, which
undergo a myofibroblastic transdifferentiation (28). Noma et
al. (27) showed that paracrine TGF- from the esophageal can-
cer cells lead to activation of the fibroblasts and vascular net-
work formation through the release of VEGF-A. Interestingly,
MMP-13 induced the secretion of VEGF-A from fibroblasts in
similar to TGF-. Moreover, TGF- induced -SMA expres-
sion in fibroblasts, indicating that the phenotypic switch from
fibroblast to myofibroblast may be caused by TGF-. MMP-13
itself could not induce -SMA expression, but it enhanced
-SMA expression induced by TGF-. Although TGF-
induced a myofibroblastic transdifferentiation of fibroblasts
and VEGF-A secretion from myofibroblasts, TGF- itself
inhibited capillary tube formation of endothelial cells (data not
shown). Previous report shows MMP-13 increases the expres-
sion of VEGF and its receptor, VEGFR-2 (19). In this study, we
could not detect VEGFR-2 expression in fibroblasts after treat-
ment with MMP-13 and/or TGF- by real-time PCR analysis
(data not shown). In addition, VEGF-A induction by MMP-13
in fibroblasts and endothelial cells was not dependent on
MMP-13 protease activity (Fig. 5, C and D). Although it is
unclear howMMP-13 promotes VEGF-A secretion from fibro-
blasts and endothelial cells, it is interesting to examine the
detailed role of MMP-13 in the tumor microenvironment.
In summary, our findings suggest thatMMP-13may directly
and indirectly promote tumor angiogenesis. In various tumors,
MMP-13 is correlated with tumor invasion, metastasis, and
poor prognosis. Therefore, we believe that MMP-13 can be a
potential target for therapeutic intervention to additionally
obstruct tumor angiogenesis in cancer patients.
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